bupropion has been researched along with oxybutynin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ioannides-Demos, LL; McNeil, JJ; Piccenna, L | 1 |
| Simon, JA | 1 |
| Advani, M; Cabezas, C; Martin, C; Puente, D; Rodriguez-Blanco, T | 1 |
| Javitz, HS; Lerman, C; Swan, GE | 1 |
2 review(s) available for bupropion and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Smoking cessation-recent advances.
Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Humans; Immunotherapy, Active; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Transdermal Patch; Treatment Outcome; United Kingdom; United States; Varenicline | 2010 |
2 trial(s) available for bupropion and oxybutynin
| Article | Year |
|---|---|
Effectiveness of a stepped primary care smoking cessation intervention: cluster randomized clinical trial (ISTAPS study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Breath Tests; Bupropion; Carbon Monoxide; Chewing Gum; Cluster Analysis; Counseling; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Motivation; Nicotine; Nicotinic Agonists; Primary Health Care; Program Evaluation; Psychological Theory; Smoking; Smoking Cessation; Social Class; Spain; Spouses; Time Factors; Transdermal Patch; Treatment Outcome; Young Adult | 2011 |
The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy.
Topics: Administration, Intranasal; Black People; Body Mass Index; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Nicotine; Nicotinic Agonists; Placebos; Recurrence; Self Report; Severity of Illness Index; Sex Factors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Transdermal Patch; White People | 2011 |
4 other study(ies) available for bupropion and oxybutynin
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
Topics: Benzazepines; Bupropion; Chewing Gum; Counseling; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Humans; Nasal Sprays; Nebulizers and Vaporizers; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Transdermal Patch; Treatment Outcome; Varenicline | 2011 |